<p>Insulet (纳斯达克:PODD - 获取免费报告) 将于 8 月 8 日星期四收盘后公布其财报。分析师预计公司将公布本季度每股盈利为 0.56 美元。Insulet 已将其 2024 财年每股盈利指引设定为 EPS，第二季度 2024 财年每股盈利指引为 EPS。有兴趣参加公司财报电话会议的人可以通过此链接进行注册。</p>
<ul>
<li>这 5 只被低估的股票准备爆发了吗？</li>
</ul>
<p>Insulet (纳斯达克:PODD - 获取免费报告) 上次公布季度财报是在 5 月 9 日星期四。这家医疗器械供应商报告本季度每股盈利为 0.73 美元，超过分析师预期的 0.39 美元，超出 0.34 美元。该公司本季度营收为 4.417 亿美元，超过分析师预期的 4.2405 亿美元。Insulet 的净资产收益率为 34.06%，净利润率为 13.14%。公司本季度营收同比增长 23.3%。在去年同期，该公司每股盈利为 0.23 美元。分析师平均预计 Insulet 本财年将实现 3 美元的每股盈利，下一财年将实现 4 美元的每股盈利。</p>
<h2>Insulet 股票表现</h2>
<p>纳斯达克 PODD 股票周四开盘价为 194.35 美元。公司的 50 天简单移动平均线为 193.88 美元，200 天简单移动平均线为 184.37 美元。公司的资产负债比为 1.72，速动比率为 2.75，流动比率为 3.74。Insulet 的 52 周最低价为 125.82 美元，52 周最高价为 281.83 美元。该公司市值为 136.1 亿美元，市盈率为 58.89，市盈增长比率为 3.45，贝塔系数为 1.16。</p>
<h2>分析师升级和降级</h2>
<ul>
<li>2024 年增长最快的 5 家医疗保健股票</li>
</ul>
<p>一些研究机构最近对 PODD 发表了评论。Canaccord Genuity Group 重申了对 Insulet 的 “买入” 评级，并在 7 月 23 日星期二发布的研究报告中给出了 234.00 美元的目标价。Raymond James 将 Insulet 的目标股价从 218.00 美元下调至 213.00 美元，并在 5 月 10 日星期五的研究报告中为该公司设定了 “表现优异” 的评级。巴克莱将 Insulet 的目标股价从 213.00 美元降至 200.00 美元，并在 5 月 13 日星期一的研究报告中为该股设定了 “持平” 评级。Wolfe Research 将 Insulet 的评级从 “同行表现” 提升至 “表现优异”，并为该公司设定了 200.00 美元的目标股价，该研究报告发布于 5 月 7 日星期二。最后，Redburn Atlantic 在 5 月 30 日星期四的研究报告中对 Insulet 进行了覆盖。他们为该公司设定了 “买入” 评级和 235.00 美元的目标股价。四家股票研究分析机构对该股的评级为持有，而 15 家机构则给予该股买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “中等买入”，目标股价为 239.18 美元。</p>
<p><strong>查看我们对 PODD 的最新股票分析</strong></p>
<h2>内部人员活动</h2>
<ul>
<li>MarketBeat‘本周股票’：直觉外科达到新高</li>
</ul>
<p>另外，董事 Timothy J. Scannell 于 6 月 10 日星期一以 190.51 美元的平均价格出售了 7,000 股 Insulet 股票。交易金额为 1,333,570.00 美元。此次交易后，该董事在公司中直接持有 35,586 股股票，价值约 6,779,488.86 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接查看。此外，董事 Timothy J. Scannell 于 5 月 28 日星期二以 180.90 美元的平均价格出售了公司的 3,300 股股票。交易金额为 596,970.00 美元。此次交易后，该董事现在直接持有公司股票 42,586 股，价值 7,703,807.40 美元。该交易已在提交给证券交易委员会的法律文件中披露，可通过此链接查看。此外，董事 Timothy J. Scannell 于 6 月 10 日星期一以 190.51 美元的平均价格出售了 7,000 股股票。交易金额为 1,333,570.00 美元。此次交易后，该董事在公司中持有 35,586 股股票，价值约 6,779,488.86 美元。此次交易的披露信息可在此处找到。在过去 90 天内，内部人员共出售了价值 2,636,286 美元的 13,931 股公司股票。目前公司股份的 0.47% 由公司内部人员持有。</p>
<h2>Insulet 公司简介（获取免费报告）</h2>
<p>Insulet Corporation 开发、制造和销售胰岛素输送系统，用于胰岛素依赖型糖尿病患者。该公司的 Omnipod 平台包括 Omnipod 5 自动胰岛素输送系统（Omnipod 5），该系统包括嵌入在 Pod 中的专有 AID 算法，通过无线蓝牙通信与第三方连续葡萄糖监测仪集成，以获取葡萄糖值；Omnipod DASH 具有蓝牙功能的 Pod，由类似智能手机的个人糖尿病管理器控制，具有彩色触摸屏用户界面；以及 Omnipod GO，一种独立的可穿戴式胰岛素输送系统，为连续 72 小时提供固定速率的快速作用胰岛素。</p>
<h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只比 Insulet 更好的股票</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>Joby Aviation 股票：上涨的理由变得更加充分</li>
<li>市值计算器：如何计算市值</li>
<li>微软双位数股价上涨的坚定公司</li>
<li>如何使用股票筛选器找到股票</li>
<li>长期投资者的 5 只激进增长股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，这则故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 预测特朗普 2016 年胜选的人士：&#34;准备选举崩溃&#34;（来自 Paradigm Press）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTE0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTE0"/></p>
<h2>现在是否值得投资 Insulet？</h2>
<p>在考虑投资 Insulet 之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该买入的股票...而 Insulet 并不在这份名单上。</p>
<p>虽然 Insulet 目前在分析师中有&#34;中等买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PODD

<p>Insulet (NASDAQ:PODD) 将在 8 月 8 日星期四收盘后发布其财报。分析师预计本季度每股收益为 0.56 美元。Insulet 上次公布财报是在 5 月 9 日，超过了分析师的预期。该公司股票的 52 周最低价为 125.82 美元，最高价为 281.83 美元。Insulet 被评为 “中等买入”，共识目标价为 239.18 美元</p>

<p>Insulet (NASDAQ:PODD - Get Free Report) is set to announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of $0.56 per share for the quarter. Insulet has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.</p>
<ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><p>Insulet (纳斯达克:PODD - 获取免费报告) 将于 8 月 8 日星期四收盘后公布其财报。分析师预计公司将公布本季度每股盈利为 0.56 美元。Insulet 已将其 2024 财年每股盈利指引设定为 EPS，第二季度 2024 财年每股盈利指引为 EPS。有兴趣参加公司财报电话会议的人可以通过此链接进行注册。</p>
<ul>
<li>这 5 只被低估的股票准备爆发了吗？</li>
</ul>
</div><p>Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.34. The company had revenue of $441.70 million during the quarter, compared to analysts' expectations of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business's quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 earnings per share. On average, analysts expect Insulet to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Insulet (纳斯达克:PODD - 获取免费报告) 上次公布季度财报是在 5 月 9 日星期四。这家医疗器械供应商报告本季度每股盈利为 0.73 美元，超过分析师预期的 0.39 美元，超出 0.34 美元。该公司本季度营收为 4.417 亿美元，超过分析师预期的 4.2405 亿美元。Insulet 的净资产收益率为 34.06%，净利润率为 13.14%。公司本季度营收同比增长 23.3%。在去年同期，该公司每股盈利为 0.23 美元。分析师平均预计 Insulet 本财年将实现 3 美元的每股盈利，下一财年将实现 4 美元的每股盈利。</p>
</div><h2>Insulet Stock Performance</h2>
<div class="lb-trans"><h2>Insulet 股票表现</h2>
</div><p>Shares of NASDAQ PODD opened at $194.35 on Thursday. The business's 50-day simple moving average is $193.88 and its 200-day simple moving average is $184.37. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. Insulet has a 52 week low of $125.82 and a 52 week high of $281.83. The firm has a market cap of $13.61 billion, a price-to-earnings ratio of 58.89, a P/E/G ratio of 3.45 and a beta of 1.16.</p>
<div class="lb-trans"><p>纳斯达克 PODD 股票周四开盘价为 194.35 美元。公司的 50 天简单移动平均线为 193.88 美元，200 天简单移动平均线为 184.37 美元。公司的资产负债比为 1.72，速动比率为 2.75，流动比率为 3.74。Insulet 的 52 周最低价为 125.82 美元，52 周最高价为 281.83 美元。该公司市值为 136.1 亿美元，市盈率为 58.89，市盈增长比率为 3.45，贝塔系数为 1.16。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<ul>
<li>5 top healthcare stocks for earnings growth in 2024</li>
</ul>
<div class="lb-trans"><h2>分析师升级和降级</h2>
<ul>
<li>2024 年增长最快的 5 家医疗保健股票</li>
</ul>
</div><p>A number of research firms have recently commented on PODD. Canaccord Genuity Group reissued a &#34;buy&#34; rating and issued a $234.00 price target on shares of Insulet in a research report on Tuesday, July 23rd. Raymond James cut their target price on shares of Insulet from $218.00 to $213.00 and set an &#34;outperform&#34; rating for the company in a research report on Friday, May 10th. Barclays lowered their price target on Insulet from $213.00 to $200.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Monday, May 13th. Wolfe Research raised Insulet from a &#34;peer perform&#34; rating to an &#34;outperform&#34; rating and set a $200.00 price objective for the company in a research report on Tuesday, May 7th. Finally, Redburn Atlantic assumed coverage on Insulet in a research note on Thursday, May 30th. They set a &#34;buy&#34; rating and a $235.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $239.18.</p>
<div class="lb-trans"><p>一些研究机构最近对 PODD 发表了评论。Canaccord Genuity Group 重申了对 Insulet 的 “买入” 评级，并在 7 月 23 日星期二发布的研究报告中给出了 234.00 美元的目标价。Raymond James 将 Insulet 的目标股价从 218.00 美元下调至 213.00 美元，并在 5 月 10 日星期五的研究报告中为该公司设定了 “表现优异” 的评级。巴克莱将 Insulet 的目标股价从 213.00 美元降至 200.00 美元，并在 5 月 13 日星期一的研究报告中为该股设定了 “持平” 评级。Wolfe Research 将 Insulet 的评级从 “同行表现” 提升至 “表现优异”，并为该公司设定了 200.00 美元的目标股价，该研究报告发布于 5 月 7 日星期二。最后，Redburn Atlantic 在 5 月 30 日星期四的研究报告中对 Insulet 进行了覆盖。他们为该公司设定了 “买入” 评级和 235.00 美元的目标股价。四家股票研究分析机构对该股的评级为持有，而 15 家机构则给予该股买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “中等买入”，目标股价为 239.18 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on PODD</strong></p>
<div class="lb-trans"><p><strong>查看我们对 PODD 的最新股票分析</strong></p>
</div><h2>Insider Activity</h2>
<ul>
<li>MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs</li>
</ul>
<div class="lb-trans"><h2>内部人员活动</h2>
<ul>
<li>MarketBeat‘本周股票’：直觉外科达到新高</li>
</ul>
</div><p>In other news, Director Timothy J. Scannell sold 7,000 shares of Insulet stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the sale, the director now directly owns 35,586 shares in the company, valued at approximately $6,779,488.86. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the company's stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $180.90, for a total transaction of $596,970.00. Following the sale, the director now directly owns 42,586 shares of the company's stock, valued at $7,703,807.40. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link. Also, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction on Monday, June 10th. The stock was sold at an average price of $190.51, for a total value of $1,333,570.00. Following the sale, the director now owns 35,586 shares in the company, valued at approximately $6,779,488.86. The disclosure for this sale can be found here. In the last 90 days, insiders sold 13,931 shares of company stock worth $2,636,286. 0.47% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>另外，董事 Timothy J. Scannell 于 6 月 10 日星期一以 190.51 美元的平均价格出售了 7,000 股 Insulet 股票。交易金额为 1,333,570.00 美元。此次交易后，该董事在公司中直接持有 35,586 股股票，价值约 6,779,488.86 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此超链接查看。此外，董事 Timothy J. Scannell 于 5 月 28 日星期二以 180.90 美元的平均价格出售了公司的 3,300 股股票。交易金额为 596,970.00 美元。此次交易后，该董事现在直接持有公司股票 42,586 股，价值 7,703,807.40 美元。该交易已在提交给证券交易委员会的法律文件中披露，可通过此链接查看。此外，董事 Timothy J. Scannell 于 6 月 10 日星期一以 190.51 美元的平均价格出售了 7,000 股股票。交易金额为 1,333,570.00 美元。此次交易后，该董事在公司中持有 35,586 股股票，价值约 6,779,488.86 美元。此次交易的披露信息可在此处找到。在过去 90 天内，内部人员共出售了价值 2,636,286 美元的 13,931 股公司股票。目前公司股份的 0.47% 由公司内部人员持有。</p>
</div><h2>Insulet Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Insulet 公司简介（获取免费报告）</h2>
</div><p>Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.</p>
<div class="lb-trans"><p>Insulet Corporation 开发、制造和销售胰岛素输送系统，用于胰岛素依赖型糖尿病患者。该公司的 Omnipod 平台包括 Omnipod 5 自动胰岛素输送系统（Omnipod 5），该系统包括嵌入在 Pod 中的专有 AID 算法，通过无线蓝牙通信与第三方连续葡萄糖监测仪集成，以获取葡萄糖值；Omnipod DASH 具有蓝牙功能的 Pod，由类似智能手机的个人糖尿病管理器控制，具有彩色触摸屏用户界面；以及 Omnipod GO，一种独立的可穿戴式胰岛素输送系统，为连续 72 小时提供固定速率的快速作用胰岛素。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Insulet</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>Joby Aviation Stock: The Case for Upside Just Got Stronger</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Conviction Firms for Microsoft's Double-Digit Stock Upside</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>5 Aggressive Growth Stocks for Long-Term Investors</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只比 Insulet 更好的股票</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>Joby Aviation 股票：上涨的理由变得更加充分</li>
<li>市值计算器：如何计算市值</li>
<li>微软双位数股价上涨的坚定公司</li>
<li>如何使用股票筛选器找到股票</li>
<li>长期投资者的 5 只激进增长股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=PODD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，这则故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 预测特朗普 2016 年胜选的人士：&#34;准备选举崩溃&#34;（来自 Paradigm Press）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTE0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8914&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Insulet right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 Insulet？</h2>
</div><p>Before you consider Insulet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Insulet 之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该买入的股票...而 Insulet 并不在这份名单上。</p>
</div><p>While Insulet currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insulet 目前在分析师中有&#34;中等买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Insulet（PODD）将于周四公布财报